NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Anthony Maida, Ph.D started a new position as Chief Clinical Officer - Translational Medicine at Mateon/Oncotelic, Inc.(3 weeks ago)

Experience

Nuclear RNA Networks
Chief Scientific Officer - Translational Medicine
Company Name Nuclear RNA Networks Part-time
Dates Employed Jul 2020 – Present

Mateon/Oncotelic, Inc.

Chief Clinical Officer - Translational Medicine
Company Name Mateon/Oncotelic, Inc. Full-time
Dates Employed Jul 2020 – Present
Location Irvine, California, United States

Northwest Biotherapeutics, Inc.

Senior Vice President - Clinial Research
Company NameNorthwest Biotherapeutics, Inc.
Dates Employed Jun 2011 – Jul 2020
Employment Duration 9 yrs 2 mos

https://www.linkedin.com/in/anthonymaida/

About
Dr. Maida, an expert in immuno-oncology, currently serves as Chief Scientific Officer - Tranlational Medicine at Nuclear RNA Networks a company focused on the interpretation of relationship of transposalble elements and disease. Dr. Maida was formerly Senior Vice President - Clinical Research at Northwest Biotherapeutics, Inc. Prior to joining Northwest Dr. Maida served as Vice President, Clinical Research and General Manager, Oncology, World-wide at PharmaNet, Inc. Prior to joining PharmaNet Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street. Dr. Maida’s skill set includes the leading execution and oversight of finance, operations, research, clinical and scientific development, regulatory and manufacturing for the development of various oncology immunotherapies. Over the past 25 years Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development. Over recent years Dr. Maida has raised, or assisted in financings, nearlyof $200 million for emerging biotechnology companies. Dr. Maida serves as an advisor, consultant and technical analyst for CMX Capital, LLC, Sagamore Bioventures, Roaring Fork Capital, Toucan Capital, North Sound Capital, The Bonnie J. Addario Lung Cancer Foundation and vFinance; the later three companies are located on the East Coast. Additionally, Dr. Maida has been retained by Abraxis BioScience, Inc., Northwest BioTherapeutics, Inc. and Takeda Chemical Industries, Ltd. (Osaka, Japan). Dr. Maida holds a Ph.D. in Immunology, a B.A. degree in Biology, a B.A. Degree in History, a MBA and a MA in toxicology. He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the Society for Immunotherapy of Cancer (SITC), and the American Chemical Society. Dr. Maida holds a patents and patent applications associated with various therapeutic modalities and approaches.